Glumetza (Metformin HCl) Patent Expiration, LOE Window & CMS Spending

Glumetza (Metformin HCl) by Santarus /Sa: Off-Patent Genericized (AB Competition), 38 AB generics, $45.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSantarus /Sa
FDA Application & PathwayN021748 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors38
2024 CMS Total Public Spend$45.8M
2024 Medicare Part D Spend$19.8M
2024 Medicaid Spend$26.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel